Clinical Outcomes and Ejaculatory Function in BPO Patients Treated With Silodosin

This observational study aims to evaluate the relationship between silodosin-induced anejaculation and clinical outcomes in male patients with benign prostatic obstruction (BPO). Silodosin is a commonly used alpha-blocker for lower urinary tract symptoms (LUTS). However, it may cause ejaculatory dysfunction, particularly anejaculation. In this study, patients receiving silodosin for the first time will be grouped based on whether they experience anejaculation or not. Treatment response will be assessed using urinary flow rate, post-void residual urine, and International Prostate Symptom Score (IPSS). Sexual function will be evaluated using the International Index of Erectile Function-5 (IIEF-5) before and after treatment. The study aims to explore whether the presence of anejaculation is associated with improved symptom relief or differences in sexual health.

NCT Number	NCT06989515
Lead Sponsor	Marmara University
Conditions	Benign Prostate Obstruction (BPO), Lower Urinary Tract Symptom, Ejaculatory Dysfunction, Anejaculation, Silodosin
Enrollment	100 participants
Start Date	2025-06-15
Primary Completion	2026-03-01 (estimated)
Study Completion	2026-06-12 (estimated)
Updated on ClinicalTrials.gov	2025-06-05